Saturday 17 October 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.48
0.12
−3.33%
Follow PASG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (169.09%) | (128.90%) | (113.78%) | (87.18%) |
+8 more TTM periods Free account |
|
| (69.20%) | (61.53%) | (55.28%) | (48.69%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(810.41%) | (243.65%) | (158.14%) | (117.13%) | |
Free Cash Flow per Share |
(10.43) | (9.37) | (9.56) | (10.17) | |
Free Cash Flow |
(33.48) | (30.04) | (30.34) | (32.32) | |
Capital Expenditures |
0.02 | 0.61 | 1.17 | 1.16 | |
| Other line items | |||||
Cash ROIC |
(117.02%) | (66.63%) | (46.63%) | (38.52%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 0.81 | 0.69 | 0.74 | |
Depreciation/Fixed assets |
0.00 | 0.79 | 0.21 | 0.20 | |
Capex/Depreciation |
0.04 | 0.92 | 1.37 | 1.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(10.44) | (9.56) | (9.93) | (10.53) | |
Capex per Share |
0.01 | 0.19 | 0.37 | 0.36 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates